FEATURED EDITORIAL
No single body integrates preclinical data components into a coherent discipline supported by shared standards, common terminology, and collective accountability.
- 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
- 2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore
- 2026 Nucleate Boston Activator Cohort Interview: Anna Kazatskaya — Fervid Therapeutics, previously Antozero
- Strategic Synthesis Of ASGCT And ASCO 2026
FEATURED APPLICATION CONTENT
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
-
High-throughput chemistry delivers speed and efficiency, but only with the right digital backbone. See how integrated automation and analytics help chemists extract more value from every plate.
-
AI‑enabled DMTA cycles connect design, experimentation, and analysis through structured data and automation, reducing manual handoffs while accelerating discovery, development, and CMC decision‑making.
-
Managing analytical data across instruments doesn’t have to slow decision-making. Learn how a vendor-neutral, multi-technique approach helps chemists access, process, and report results efficiently.
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
- 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
- 2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- SK Life Science, Inc. Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension
- Optimi Health Launches Standardized Microdose Psilocybin Products For Clinical Research
- Protillion Biosciences Announces Drug Discovery Collaboration With Merck
- IDBS And Alchemi Partner To Accelerate Biopharma Regulatory Filings With Compliant AI Agents
- Clinical Trials On Alzheimer's Disease Conference And Alzheimer's Drug Discovery Foundation Partner To Advance Emerging Biotech Innovation At CTAD 2026
- Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence In Translational Research And Drug Discovery
- Pelago Bioscience Acquires RG Discovery, Forming An Integrated Drug Discovery Partner Spanning Biology And Chemistry
- TuHURA Biosciences Files Investigational New Drug Application For Evaluation Of The TBS-2025 VISTA Inhibiting Antibody In Molecularly Defined Subsets Of AML And Other Blood Related Cancers
- Harbour BioMed Announces NMPA Acceptance Of IND Application For HBM7004 For The Treatment Of Advanced Solid Tumors
- Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical And AI Companies To Accelerate AI-enabled Drug Discovery
ARCHIVED NEWSLETTER
- 06.16.26 -- Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort
- 06.09.26 -- Validation And Trust Are Biggests Barriers To Organ On Chip Adoption
- 06.06.26 -- Drug Discovery Online Best Of May
- 05.19.26 -- From Urine-Derived To Recombinant Precision: KLK1 Reimagined For Preeclampsia
- 05.02.26 -- Drug Discovery Online Best Of April
